header logo image

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

August 4th, 2021 1:53 am

On target to grow the broad product pipeline with at least 3 additional programmes before end 2021Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV

See more here:
Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick